Stock listing
NASDAQ:UNCY Unicycive Therapeutics, Inc. Stock
Home listing (NASDAQ) of Unicycive Therapeutics, Inc.
Follow Unicycive Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:UNCY
$3.35 USD -0.22 (-6.2%)
Close on Nov 20, 2026
- Day range
- $3.35 – $3.62 USDNov 20, 2026
- Volume
- 1.36M sharesNov 20, 2026
- Market cap
- $97.77M USDAt the close on Nov 20, 2026 · price × 29.18M shares outstanding
- 52-week range
- $3.33 – $8.74 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.05M USDMedian day 891,630 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:UNCY · Home | $3.35 USD | -0.22 (-6.2%) | 1,355,565 | $3.48 | $3.615 | $3.345 | $3.57 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:UNCY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.35 | -0.22 | -6.2% | $3.48 | $3.615 | $3.345 | 1,355,565 | |
| $3.57 | -0.13 | -3.5% | $3.70 | $3.83 | $3.555 | 1,387,681 | |
| $3.70 | 0.00 | 0.0% | $3.69 | $3.77 | $3.59 | 1,107,391 | |
| $3.70 | +0.15 | +4.2% | $3.58 | $3.78 | $3.55 | 1,237,545 | |
| $3.55 | -0.09 | -2.5% | $3.63 | $3.688 | $3.52 | 679,926 | |
| $3.64 | -0.14 | -3.7% | $3.70 | $3.71 | $3.56 | 782,192 | |
| $3.78 | +0.12 | +3.3% | $3.68 | $3.855 | $3.639 | 631,084 | |
| $3.66 | -0.04 | -1.1% | $3.62 | $3.78 | $3.60 | 641,316 | |
| $3.70 | +0.15 | +4.2% | $3.55 | $3.76 | $3.50 | 842,147 | |
| $3.55 | +0.07 | +2.0% | $3.46 | $3.59 | $3.454 | 602,365 | |
| $3.48 | -0.27 | -7.2% | $3.69 | $3.72 | $3.37 | 1,466,553 | |
| $3.75 | +0.16 | +4.5% | $3.67 | $3.79 | $3.63 | 529,867 | |
| $3.59 | +0.10 | +2.9% | $3.50 | $3.64 | $3.48 | 940,807 | |
| $3.49 | -0.25 | -6.7% | $3.60 | $3.61 | $3.33 | 2,234,597 | |
| $3.74 | -0.07 | -1.8% | $3.77 | $3.93 | $3.623 | 977,989 | |
| $3.81 | +0.05 | +1.3% | $3.815 | $3.87 | $3.74 | 891,630 | |
| $3.76 | +0.15 | +4.2% | $3.60 | $3.77 | $3.58 | 1,129,015 | |
| $3.61 | +0.03 | +0.8% | $3.60 | $3.69 | $3.48 | 1,340,066 | |
| $3.58 | -0.31 | -8.0% | $3.90 | $3.90 | $3.534 | 1,316,093 | |
| $3.89 | -0.05 | -1.3% | $3.95 | $4.017 | $3.705 | 1,212,400 | |
| $3.94 | +0.07 | +1.8% | $3.87 | $4.00 | $3.83 | 742,800 | |
| $3.87 | +0.07 | +1.8% | $4.08 | $4.18 | $3.825 | 1,437,900 | |
| $3.80 | +0.29 | +8.3% | $3.53 | $3.87 | $3.52 | 1,207,900 | |
| $3.51 | +0.15 | +4.5% | $3.37 | $3.64 | $3.355 | 1,126,600 | |
| $3.36 | -0.23 | -6.4% | $3.58 | $3.595 | $3.35 | 1,102,300 | |
| $3.59 | -0.11 | -3.0% | $3.70 | $3.708 | $3.56 | 893,000 | |
| $3.70 | -0.03 | -0.8% | $3.73 | $3.81 | $3.59 | 1,208,800 | |
| $3.73 | -0.32 | -7.9% | $3.99 | $4.02 | $3.67 | 1,836,600 | |
| $4.05 | -0.06 | -1.5% | $4.10 | $4.11 | $3.99 | 912,800 | |
| $4.11 | +0.04 | +1.0% | $4.07 | $4.20 | $4.05 | 551,400 | |
| $4.07 | -0.11 | -2.6% | $4.16 | $4.199 | $4.03 | 1,176,100 | |
| $4.18 | -0.05 | -1.2% | $4.15 | $4.22 | $4.08 | 590,700 | |
| $4.23 | +0.04 | +1.0% | $4.20 | $4.294 | $4.15 | 785,400 | |
| $4.19 | -0.03 | -0.7% | $4.22 | $4.275 | $4.12 | 681,400 | |
| $4.22 | -0.33 | -7.3% | $4.62 | $4.62 | $4.09 | 1,510,100 | |
| $4.55 | -0.145 | -3.1% | $4.71 | $4.76 | $4.545 | 1,068,800 | |
| $4.695 | +0.145 | +3.2% | $4.61 | $4.81 | $4.574 | 862,700 | |
| $4.55 | -0.09 | -1.9% | $4.66 | $4.70 | $4.28 | 2,306,600 | |
| $4.64 | -0.055 | -1.2% | $4.66 | $4.68 | $4.53 | 601,500 | |
| $4.695 | -0.115 | -2.4% | $4.83 | $4.85 | $4.66 | 494,100 | |
| $4.81 | 0.00 | 0.0% | $4.81 | $4.855 | $4.62 | 660,300 | |
| $4.81 | -0.15 | -3.0% | $4.94 | $4.96 | $4.73 | 771,800 | |
| $4.96 | +0.19 | +4.0% | $4.80 | $4.97 | $4.76 | 587,700 | |
| $4.77 | -0.03 | -0.6% | $4.85 | $4.85 | $4.745 | 448,400 | |
| $4.80 | +0.03 | +0.6% | $4.80 | $4.85 | $4.76 | 1,108,400 | |
| $4.77 | -0.01 | -0.2% | $4.86 | $4.88 | $4.71 | 647,200 | |
| $4.78 | +0.07 | +1.5% | $4.85 | $4.90 | $4.691 | 904,000 | |
| $4.71 | -0.44 | -8.5% | $5.15 | $5.15 | $4.71 | 1,691,100 | |
| $5.15 | -0.14 | -2.6% | $5.27 | $5.35 | $5.13 | 671,000 | |
| $5.29 | -0.02 | -0.4% | $5.34 | $5.40 | $5.22 | 1,116,700 | |
| $5.31 | +0.19 | +3.7% | $5.07 | $5.62 | $5.04 | 1,241,800 | |
| $5.12 | +0.09 | +1.8% | $5.03 | $5.14 | $5.01 | 907,000 | |
| $5.03 | -0.13 | -2.5% | $5.13 | $5.22 | $5.025 | 817,200 | |
| $5.16 | -0.14 | -2.6% | $5.24 | $5.24 | $5.12 | 492,900 | |
| $5.30 | +0.11 | +2.1% | $5.20 | $5.34 | $5.08 | 836,100 | |
| $5.19 | +0.14 | +2.8% | $5.10 | $5.22 | $5.06 | 760,500 | |
| $5.05 | -0.15 | -2.9% | $5.13 | $5.21 | $5.04 | 671,300 | |
| $5.20 | -0.065 | -1.2% | $5.27 | $5.27 | $5.13 | 574,300 | |
| $5.265 | -0.235 | -4.3% | $5.50 | $5.50 | $5.26 | 609,200 | |
| $5.50 | +0.07 | +1.3% | $5.43 | $5.515 | $5.42 | 366,200 | |
| $5.43 | -0.04 | -0.7% | $5.46 | $5.55 | $5.35 | 906,200 | |
| $5.47 | +0.13 | +2.4% | $5.40 | $5.52 | $5.32 | 417,050 | |
| $5.34 | -0.29 | -5.2% | $5.64 | $5.64 | $5.26 | 742,955 | |
| $5.63 | +0.18 | +3.3% | $5.51 | $5.77 | $5.50 | 1,013,100 | |
| $5.45 | -0.13 | -2.3% | $5.60 | $5.68 | $5.41 | 643,200 |
Splits
1 split · NASDAQ:UNCY · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:UNCY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 33 slides
Latest news
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Nov 16, 2026
Closed $3.70 (+4.2%) on Nov 16, 2026
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 4, 2026
Closed $3.75 (+4.5%) on Nov 4, 2026
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
Oct 21, 2026
Closed $3.87 (+1.8%) on Oct 21, 2026
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Oct 1, 2026
Closed $4.55 (-3.1%) on Oct 1, 2026
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
Sep 29, 2026
Closed $4.55 (-1.9%) on Sep 29, 2026
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 1, 2026
Closed $5.05 (-2.9%) on Sep 1, 2026
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Aug 12, 2026
Closed $5.39 (+7.8%) on Aug 12, 2026
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Closed $8.17 (+2.8%) on May 12, 2026
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Apr 9, 2026
Closed $6.65 (+3.1%) on Apr 9, 2026
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Mar 30, 2026
Closed $6.11 (-4.4%) on Mar 30, 2026
Unicycive Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 110 in all · newest Nov 16, 2026 · oldest 2021
- Decks
- 4 decks · latest November 2026
Where Unicycive Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:UNCY · Home listing · This page | NASDAQ | United States | USD |
| BOATS:UNCY | BOATS | United States | USD |
Valuation
Price/book 1.9× against a median of 2.7×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $39.32M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.09
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Unicycive Therapeutics, Inc. · NASDAQ:UNCY | US$97.77M | US$39.32M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 1.09 |
| BRIM Biotechnology, Inc. · TWSE:6885 | US$100.3M | US$70.70M | n/a | 220× | n/a | 2.1× | n/a | 0.0× | n/a |
| Minerva Neurosciences, Inc · NASDAQ:NERV | US$99.67M | US$22.73M | n/a | n/a | n/a | n/a | n/a | n/a | 1.68 |
| NovaBridge Biosciences · NASDAQ:NBP | US$96.28M | US$68.30M | n/a | n/a | n/a | 3.2× | n/a | 0.0× | 1.37 |
| Wuhan YZY Biopharma Co., Ltd. Class H · HKEX:2496 | US$96.17M | US$105.6M | n/a | 7.8× | n/a | n/a | −53.2% | n/a | n/a |
| PDS Biotechnology Corporation · NASDAQ:PDSB | US$95.39M | US$80.15M | n/a | n/a | n/a | 7.1× | n/a | 0.0× | 2.04 |
| Immunic, Inc. · NASDAQ:IMUX | US$95.37M | −US$36.09M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.51 |
| NRX Pharmaceuticals, Inc. · NASDAQ:NRXP | US$95.31M | US$76.46M | n/a | 17.7× | n/a | n/a | −458.5% | n/a | 2.23 |
| Allergy Therapeutics plc · LSE:AGY | US$95.27M | US$117.1M | n/a | 1.6× | n/a | 17.1× | −72.9% | 6.3× | n/a |
| Voyager Therapeutics, Inc. · NASDAQ:VYGR | US$95.21M | −US$11.60M | n/a | −0.5× | n/a | 0.7× | −416.3% | 0.0× | 1.45 |
| Outlook Therapeutics, Inc. · NASDAQ:OTLK | US$94.94M | US$83.70M | n/a | n/a | n/a | n/a | n/a | n/a | 1.10 |
| Median of the others | US$95.38M | US$73.58M | 7.8× | 2.7× | −244.6% | 0.0× | 1.51 |
Forecasts
8 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 26.30 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.26 · 8 analysts
- Revenue, year to Dec 2026
- 1.28M · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Shalabh Gupta | Founder, President, Chief Executive Officer, and Chairman of the Board |
Board
| Director | Role |
|---|---|
| Shalabh Gupta | Founder, President, Chief Executive Officer, and Chairman of the Board |
| Meredith Manning | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | +4.2% |
| Q2 2026 | Aug 12, 2026 · Before open | +7.8% |
| Q1 2026 | May 12, 2026 | +7.0% |
| Q4 2025 | Mar 30, 2026 · Before open | −4.4% |
| Q3 2025 | Nov 12, 2025 · Before open | +7.3% |
| Q2 2025 | Aug 14, 2025 · Before open | +5.0% |
| Q1 2025 | May 14, 2025 · Before open | −7.9% |
| Q4 2024 | Mar 31, 2025 | −11.1% |
| Q3 2024 | Nov 13, 2024 · Before open | −1.2% |
| Q2 2024 | Aug 14, 2024 · Before open | +33.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | 0.0% |
| Q4 2023 | Mar 28, 2024 · After close | +2.2% |
| Q3 2023 | Nov 14, 2023 · After close | +0.6% |
| Q2 2023 | Aug 14, 2023 · After close | −7.4% |
| Q1 2023 | May 16, 2023 · Before open | −4.2% |
| Q4 2022 | Mar 31, 2023 · Before open | +11.7% |
| Q3 2022 | Nov 14, 2022 · Before open | −5.6% |
| Q2 2022 | Aug 15, 2022 · After close | −1.4% |
| Q1 2022 | May 12, 2022 · Before open | −2.8% |
| Q4 2021 | Mar 31, 2022 · Before open | −2.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 33 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 33 slides | October 2026 |
| Technical Presentation (June 2024) | Technical | 29 slides | Jun 25, 2024 |
| Corporate Update (December 2022) | Corporate update | 12 slides | Dec 28, 2022 |
IPO
Priced at US$5.00 a unit on Jul 13, 2021.
- Price
- US$5.00 a unit
- Units offered
- 5,000,000 units
- Offering size
- US$25 million
- Underwriters' option
- Up to 750,000 more units
- Listing
- UNCY on the Nasdaq Capital Market
- Underwriter
- Roth Capital Partners
- Units delivered
- On or about Jul 15, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 15, 2020 |
| Filed publicly | May 21, 2021 |
| Amended 5 times | Newest Jul 12, 2021 |
| Shares registered with an exchange | Jul 6, 2021 |
| Declared effective by the SEC | Jul 12, 2021 |
| Final prospectus, with the price | Jul 14, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 14, 2021 |
| EFFECT · Notice that a registration is effective | Jul 12, 2021 |
| S-1/A · Registration statement, amended | Jul 12, 2021 |
| S-1/A · Registration statement, amended | Jul 12, 2021 |
| CORRESP · Letter to the SEC | Jul 8, 2021 |
| CORRESP · Letter to the SEC | Jul 8, 2021 |
| CORRESP · Letter to the SEC | Jul 7, 2021 |
| CERT · Exchange's certificate of listing | Jul 7, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 6, 2021 |
| CORRESP · Letter to the SEC | Jul 6, 2021 |
All 34 filings
Open IPO · From the cover of the final prospectus (424B4) filed Jul 14, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 675.0K | 951.0K | 0 | 0 | 0 | |
| Cost of revenue | 572.0K | 428.0K | 284.0K | 7.00K | 1.00K | |||
| Gross profit | -572.0K | -428.0K | 675.0K | 951.0K | -1.00K | |||
| Research and development | 9.12M | 20.0M | 12.9M | 12.4M | 6.08M | 1.01M | 795.0K | 344.0K |
| Selling, general and administrative | 20.4M | 12.1M | 8.55M | 383.0K | 245.0K | 58.0K | 1.17M | 608.0K |
| Operating income | -29.5M | -32.1M | -20.8M | -18.1M | -8.98M | -2.02M | -1.96M | -952.0K |
| Depreciation and amortization | 34.0K | 22.0K | 9.00K | 428.0K | 468.0K | 63.0K | 1.96M | 952.0K |
| EBITDA | -29.5M | -32.1M | -20.8M | -17.6M | -8.51M | -1.96M | 0 | 0 |
| Interest expense | 71.0K | 71.0K | 82.0K | 6.00K | 628.0K | 244.0K | 139.0K | 0 |
| Income before tax | -26.6M | -36.7M | -30.5M | -18.1M | -10.0M | -2.26M | -2.17M | -1.12M |
| Income tax | -1.09M | 116.1K | 6.00K | 615.0K | 244.0K | 139.0K | -952.0K | |
| Net income | -26.6M | -36.7M | -30.5M | -18.1M | -10.0M | -2.26M | -2.30M | -1.12M |
| Earnings per share, basic | -1.67 | -5.65 | -1.28 | -1.20 | -0.86 | -0.27 | -1.51 | -0.73 |
| Earnings per share, diluted | -1.67 | -5.65 | -1.28 | -1.20 | -0.86 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 29.2M | 26.1M | 9.70M | 455.0K | 16.6M | 0 | 15.0K | 25.0K |
| Short-term investments | 12.1M | 0 | ||||||
| Inventory | 2.19M | 1.83M | ||||||
| Current assets | 49.0M | 30.9M | 13.4M | 2.64M | 18.4M | 204.0K | 19.0K | 29.0K |
| Property, plant and equipment | 66.0K | 75.0K | 26.0K | 22.0K | 28.0K | |||
| Total assets | 49.1M | 31.7M | 14.2M | 2.82M | 18.7M | 204.0K | 19.0K | 29.0K |
| Accounts payable | 383.0K | 1.06M | 839.0K | 892.0K | 742.0K | 184.0K | 322.0K | 60.0K |
| Current liabilities | 18.9M | 24.1M | 17.5M | 3.28M | 2.10M | 2.88M | 903.0K | 1.24M |
| Total debt | 199.0K | 773.0K | 811.0K | 201.0K | 335.0K | 2.51M | 460.0K | 1.05M |
| Total liabilities | 18.9M | 24.2M | 18.0M | 3.28M | 2.26M | 2.88M | 903.0K | 1.24M |
| Shareholders' equity | 30.2M | 7.43M | -3.81M | -466.0K | 16.5M | -2.67M | -884.0K | -1.21M |
| Shares outstanding | 22.1M | 11.4M | 34.8M | 15.2M | 15.0M | 8.51M | 1.52M | 1.52M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -31.3M | -28.6M | -18.3M | -15.7M | -5.77M | -1.46M | -1.18M | -775.0K |
| Capital spending | -24.0K | -72.0K | -12.0K | -2.00K | -29.0K | -29.0K | -29.0K | -29.0K |
| Free cash flow | -31.3M | -28.6M | -18.3M | -15.7M | -5.80M | -1.46M | -1.18M | -775.0K |
| Cash from investing | -12.1M | -72.0K | -12.0K | -2.00K | -29.0K | -29.0K | -29.0K | -29.0K |
| Cash from financing | 46.5M | 45.1M | 27.5M | -471.0K | 22.4M | 1.44M | 1.17M | 800.0K |
| Dividends paid | 0 | -1.09M | -900.0K | |||||
| Change in cash | 3.06M | 16.4M | 9.25M | -16.1M | 16.6M | -15.0K | -10.0K | 25.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Jul 28, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 28, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 2, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | Jun 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 22, 2026 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Jun 16, 2026 | Other filings | SEC |
| 4/A · Change in ownership, amended | Jun 15, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 15, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 15, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 15, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 15, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 15, 2026 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Jun 11, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 11, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 5, 2026 | Material contract | SEC |
| S-3 · Registration statement | Jun 5, 2026 | Offer document | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | May 5, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 6, 2026 | Management or board change | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 23, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 14, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 18, 2025 | Current report | SEC |
| 8-K · Current report | Aug 15, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2025 | Current report | SEC |
| 8-K · Current report | Jun 30, 2025 | Results | SEC |
| 8-K · Current report | Jun 20, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jun 13, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 10, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 9, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | May 21, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | May 21, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 21, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | May 7, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Apr 14, 2025 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Apr 1, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 7, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 20, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 20, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Nov 21, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 18, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 15, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Nov 14, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| S-3 · Registration statement | Nov 13, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Nov 13, 2024 | Big-stake notice | SEC |
| POS AM · Amendment to an effective registration | Nov 13, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 24, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Jul 18, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jul 17, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jul 16, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 15, 2024 | Current report | SEC |
| 8-K · Current report | Jul 15, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Jul 11, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 8, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jul 5, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 2, 2024 | Material contract | SEC |
| 8-K · Current report | Jun 26, 2024 | Current report | SEC |
| 8-K · Current report | Jun 25, 2024 | Current report | SEC |
| 8-K · Current report | Jun 20, 2024 | Meeting outcome | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | May 8, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2024 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| D | Mar 20, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 14, 2024 | Material contract | SEC |
| 8-K · Current report | Mar 14, 2024 | Material contract | SEC |
| 8-K · Current report | Feb 21, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 2, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 22, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Dec 8, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 23, 2023 | Current report | SEC |
| 8-K · Current report | Sep 25, 2023 | Current report | SEC |
| 4 · Change in ownership | Sep 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 7, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 7, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 6, 2023 | Management or board change | SEC |
| 8-K · Current report | Aug 31, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 30, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 4, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 1, 2023 | Other filings | SEC |
| 8-K · Current report | Jul 31, 2023 | Current report | SEC |
| 8-K · Current report | Jul 26, 2023 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jul 19, 2023 | Other filings | SEC |
| SC 13G · Big-stake notice | Jul 14, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2023 | Insider trade | SEC |
| S-3 · Registration statement | Jul 12, 2023 | Offer document | SEC |
| SC 13G · Big-stake notice | Jul 6, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jul 6, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jun 29, 2023 | Current report | SEC |
| 8-K · Current report | Jun 26, 2023 | Meeting outcome | SEC |
This page holds 200 of 311 filings. Open Filings
Cap table
Built by 6ix from Unicycive Therapeutics, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 29,184,509
- Fully diluted
- 29,184,509
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 29,184,509 | Nov 16, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 16, 2026 | 29,184,509 |
| Sep 30, 2026 | 29,110,352 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Sandeep Steve Laumas Other companies: Instil Bio, Inc. (Chief Financial Officer & Chief Business Officer · Since at least Mar 18, 2021); BioXcel Therapeutics, Inc. (Director · Since at least Mar 7, 2018) | Director · Since at least Jul 12, 2021 |
| Gaurav Aggarwal Other companies: Geron Corporation (Director · Nov 26, 2023 – May 21, 2025 · Past) | Director · Since at least Oct 9, 2024 |
| John L Ryan Other companies: Kadmon Holdings Inc (EVP, Chief Medical Officer · Jul 26, 2016 – Nov 9, 2021 · Past) | Director · Jul 12, 2021 – Sep 5, 2023 · Past |
| Sara Kenkare-Mitra Other companies: Alector, Inc. (President and Head of R&D · Since at least Dec 15, 2021) | Director · Since at least Sep 5, 2023 |
| Brigitte Schiller | Director · Jul 12, 2021 – Jul 15, 2022 · Past |
| Douglas Jermasek | EVP, Corporate Strategy · Since at least Nov 21, 2022 |
| John Townsend | CFO · Since at least Jul 12, 2021 |
| Meredith Manning | Board Member · Since at least Oct 1, 2026 |
| Pramod Gupta | EVP, Pharmaceuticals and BD · Since at least Jul 12, 2021 |
| Shalabh Gupta | Founder, President, Chief Executive Officer, and Chairman of the Board · Since at least Jul 12, 2021 |
Log in to ask 6ix AI your own questions about Unicycive Therapeutics, Inc.